RxDoctor Payments Data

Jeffrey Hale

Family · Visalia, CANPI 1437836145

Payments from drug & device makers

$4,752in general payments, 2019–2025

Across 345 payments — averaging $13.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$690
  • AbbVie$687
  • Arcutis Biotherapeutics, Inc.$654
  • Johnson & Johnson$564
  • Sanofi$462
  • Verrica Pharmaceuticals Inc.$392
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$4,738100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,752 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$222,234
Medicare patients
317
Services billed
3,865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab13$42,618
JubliaEfinaconazole28$39,717
OpzeluraRuxolitinib Phosphate13$36,873
VtamaTapinarof16$21,027
Tacrolimus74$17,183
Clobetasol Propionate183$9,759
ZoryveRoflumilast11$8,945
Ketoconazole188$6,588
Metronidazole39$3,474
MupirocinMupirocin Calcium18$3,227
Ivermectin12$2,961
Desonide18$2,437
Fluocinonide49$2,246
Tretinoin22$1,735
Hydrocortisone89$1,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$690$36,87313 claims
Dermavant Sciences, Inc.Vtama$222$21,02716 claims
Arcutis Biotherapeutics, Inc.Zoryve$654$8,94511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Visalia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →